睦暮
Lv714
4190 积分
2022-04-22 加入
-
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
1个月前
已完结
-
Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer
6个月前
已完结
-
How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
6个月前
已完结
-
The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection
6个月前
已完结
-
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
6个月前
已完结
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
6个月前
已完结
-
Hyperoside prevents doxorubicin‐induced cardiotoxicity by inhibiting NOXs/ROS/NLRP3 inflammasome signaling pathway
8个月前
已完结
-
REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort
1年前
已关闭
-
Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2)
1年前
已关闭
-
Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial
1年前
已关闭